Format
Sort by

Send to

Choose Destination

Links from MedGen

Items: 1 to 20 of 613

1.

EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.

Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M.

Eur J Neurol. 2013 Jan;20(1):16-34. doi: 10.1111/ene.12022. Review. Erratum in: Eur J Neurol. 2013 Feb;20(2):406.

PMID:
23279440
2.

The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI.

Huynh DP, Scoles DR, Nguyen D, Pulst SM.

Hum Mol Genet. 2003 Oct 15;12(20):2587-97.

PMID:
12925569
3.

Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.

Hatano T, Okuzumi A, Kamagata K, Daida K, Taniguchi D, Hori M, Yoshino H, Aoki S, Hattori N.

J Neural Transm (Vienna). 2017 Feb 3. doi: 10.1007/s00702-017-1688-9. [Epub ahead of print] Review.

PMID:
28160151
4.

In Silico Analysis of SNPs in PARK2 and PINK1 Genes That Potentially Cause Autosomal Recessive Parkinson Disease.

Bakhit YH, Ibrahim MO, Amin M, Mirghani YA, Hassan MA.

Adv Bioinformatics. 2016;2016:9313746. doi: 10.1155/2016/9313746.

5.

PARK2-dependent mitophagy induced by acidic postconditioning protects against focal cerebral ischemia and extends the reperfusion window.

Shen Z, Zheng Y, Wu J, Chen Y, Wu X, Zhou Y, Yuan Y, Lu S, Jiang L, Qin Z, Chen Z, Hu W, Zhang X.

Autophagy. 2017 Jan 19:0. doi: 10.1080/15548627.2016.1274596. [Epub ahead of print]

PMID:
28103118
6.

Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons.

Suzuki S, Akamatsu W, Kisa F, Sone T, Ishikawa KI, Kuzumaki N, Katayama H, Miyawaki A, Hattori N, Okano H.

Biochem Biophys Res Commun. 2017 Jan 29;483(1):88-93. doi: 10.1016/j.bbrc.2016.12.188.

PMID:
28057485
7.

Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis.

Gong Y, Schumacher SE, Wu WH, Tang F, Beroukhim R, Chan TA.

Neoplasia. 2017 Feb;19(2):75-83. doi: 10.1016/j.neo.2016.12.006.

8.

A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.

Shi CH, Zhang SY, Yang ZH, Yang J, Shang DD, Mao CY, Liu H, Hou HM, Shi MM, Wu J, Xu YM.

Mov Disord. 2016 Dec;31(12):1905-1909. doi: 10.1002/mds.26828.

PMID:
27943471
9.
10.

PARK2 Microduplication: Clinical and Molecular Characterization of a Further Case and Review of the Literature.

Palumbo O, Palumbo P, Leone MP, Stallone R, Palladino T, Vendemiale M, Palladino S, Papadia F, Carella M, Fischetto R.

Mol Syndromol. 2016 Oct;7(5):282-286.

PMID:
27867343
11.

Phospho-ubiquitin-PARK2 complex as a marker for mitophagy defects.

Callegari S, Oeljeklaus S, Warscheid B, Dennerlein S, Thumm M, Rehling P, Dudek J.

Autophagy. 2017 Jan 2;13(1):201-211. doi: 10.1080/15548627.2016.1254852.

PMID:
27846363
12.

Definition of a putative pathological region in PARK2 associated with autism spectrum disorder through in silico analysis of its functional structure.

Conceição IC, Rama MM, Oliveira B, Café C, Almeida J, Mouga S, Duque F, Oliveira G, Vicente AM.

Psychiatr Genet. 2017 Apr;27(2):54-61. doi: 10.1097/YPG.0000000000000159.

PMID:
27824727
13.

Second mutation in PARK2 is absent in patients with sporadic Parkinson's disease and heterozygous exonic deletions/duplications in parkin gene.

Shulskaya MV, Shadrina MI, Fedotova EY, Abramycheva NY, Limborska SA, Illarioshkin SN, Slominsky PA.

Int J Neurosci. 2016 Nov 16:1-4. [Epub ahead of print]

PMID:
27798970
14.

A novel PINK1- and PARK2-dependent protective neuroimmune pathway in lethal sepsis.

Kang R, Zeng L, Xie Y, Yan Z, Zhou B, Cao L, Klionsky DJ, Tracey KJ, Li J, Wang H, Billiar TR, Jiang J, Tang D.

Autophagy. 2016 Dec;12(12):2374-2385.

PMID:
27754761
15.

 PARK2 polymorphisms predict disease progression in patients infected with hepatitis C virus.

Al-Qahtani AA, Al-Anazi MR, Al-Zoghaibi FA, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, Khalak H, Al-Ahdal MN.

Ann Hepatol. 2016 Nov-Dec 2016;15(6):824-833.

16.

Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus.

Tatura R, Kraus T, Giese A, Arzberger T, Buchholz M, Höglinger G, Müller U.

Parkinsonism Relat Disord. 2016 Dec;33:115-121. doi: 10.1016/j.parkreldis.2016.09.028.

PMID:
27717584
17.

Preservation Analysis of Macrophage Gene Coexpression Between Human and Mouse Identifies PARK2 as a Genetically Controlled Master Regulator of Oxidative Phosphorylation in Humans.

Codoni V, Blum Y, Civelek M, Proust C, Franzén O; Cardiogenics Consortium.; IDEM Leducq Consortium CADGenomics., Björkegren JL, Le Goff W, Cambien F, Lusis AJ, Trégouët DA.

G3 (Bethesda). 2016 Oct 13;6(10):3361-3371. doi: 10.1534/g3.116.033894.

18.

Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile Parkinsonism.

Kirola L, Behari M, Shishir C, Thelma BK.

Parkinsonism Relat Disord. 2016 Oct;31:124-128. doi: 10.1016/j.parkreldis.2016.07.014.

PMID:
27496670
19.

Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease.

Lee S, She J, Deng B, Kim J, de Andrade M, Na J, Sun Z, Wampfler JA, Cunningham JM, Wu Y, Limper AH, Aubry MC, Wendt C, Biterman P, Yang P, Lou Z.

Oncotarget. 2016 Jul 12;7(28):44211-44223. doi: 10.18632/oncotarget.9954.

20.

Association of a PARK2 Germline Variant and Epithelial Ovarian Cancer in a Southern Brazilian Population.

Klimczak PF, Ventury DH, Faucz FR, Settas N, Machado de Souza C, Sotomaior VS.

Oncology. 2016;91(2):101-5. doi: 10.1159/000446657.

PMID:
27286703
Items per page

Supplemental Content

Support Center